Cumberland Pharmaceuticals Inc CPIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CPIX is a good fit for your portfolio.
News
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
-
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
-
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
-
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS
-
SEC Fines 5 Public Companies, Insiders Over Reporting Failures
Trading Information
- Previous Close Price
- $1.44
- Day Range
- $1.50–1.53
- 52-Week Range
- $1.44–2.34
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $21.69 Mil
- Volume/Avg
- 7,934 / 10,019
Key Statistics
- Price/Earnings (Normalized)
- 4.47
- Price/Sales
- 0.55
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 3.68%
Company Profile
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 91
- Website
- https://www.cumberlandpharma.com
Valuation
|
Metric
|
CPIX
|
|---|---|
Price/Earnings (Normalized) | 4.47 |
Price/Book Value | 0.72 |
Price/Sales | 0.55 |
Price/Cash Flow | 14.80 |
Price/Earnings
CPIX
Financial Strength
|
Metric
|
CPIX
|
|---|---|
Quick Ratio | 1.00 |
Current Ratio | 1.28 |
Interest Coverage | −8.84 |
Quick Ratio
CPIX
Profitability
|
Metric
|
CPIX
|
|---|---|
Return on Assets (Normalized) | −4.57% |
Return on Equity (Normalized) | −11.50% |
Return on Invested Capital (Normalized) | −6.87% |
Return on Assets
CPIX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Hqkfyfjgz | Xft | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Vbtqgndc | Hlsmkl | $69.1 Bil | |
HLN
| Haleon PLC ADR | Rmqpvzcbr | Kkgv | $37.6 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Lzdbnpnl | Skks | $15.6 Bil | |
VTRS
| Viatris Inc | Myzyxrzw | Ghbj | $13.8 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Rnynrdr | Rnpsc | $12.4 Bil | |
CTLT
| Catalent Inc | Pycrxblw | Wckzb | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Mkvfmpcpb | Fcd | $4.5 Bil | |
CURLF
| Curaleaf Holdings Inc | Xrcwvvjp | Hpjvf | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Ffxqfhh | Lmjjvnq | $3.5 Bil |